



Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Pharmacy Benefits Prior Authorization Help Desk
Short-acting, Long-acting, Methadone Opioids Prior Authorization (PA)

Instructions: Completion of this prior authorization (PA) form is required for timely processing of the prescription. Complete and fax this form back to Kaiser Permanente within 24 hours at fax: 1-866-331-2104. For questions or concerns, call 1-866-331-2103. The KPMAS VA Medicaid Formulary can be found at:

https://healthy.kaiserpermanente.org/static/health/pdfs/formulary/mid/mid\_medicaid.pdf

CDC Guidelines for Opioid prescribing for Chronic Pain: OPIOIDS ARE NOT RECOMMENDED AS FIRST-LINE TREATMENT FOR CHRONIC PAIN. Please see http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm for additional information.

Prior Authorization is required for:

- 1) All Long Acting Opioids
2) Any Short-Acting Opioid prescribed for > 7 days or two (2) 7 day supplies in a in a 60 day period. The Virginia BOM Regulations limit the treatment of acute pain with opioids to 7 days and post-op pain to no more than 14 days.
3) Any cumulative opioid prescription exceeding 120 morphine milligram equivalents (MME) per day.

1-Patient Information

Patient Name: Kaiser Medical ID#:
Date of Birth: Gender: Male Female Phone #:

2-Provider Information

Provider Name: Provider NPI:
Provider Address: Phone Fax
Specialty: Oncologist Hematology Chronic Pain Specialist Palliative Care Other:
Please check the box that applies:
Standard Review (72 hours)
Expedited Review (24 hours): By checking this box, I certify that applying 72 hours standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.
Provider Signature

3-Important Exclusion Criteria

- 1) Does the prescriber attest that the patient has intractable pain from active cancer, end-of-life? Yes No
If Yes, please select what applies sign and submit the form, no further information is required. Active cancer Hospice Palliative care
2) Is the patient on remission from cancer, and prescriber is safely weaning patient off of opioids with a tapering plan? Yes No
If Yes, please sign and submit, no further information is required
3) Is the patient on long-term care facility? Yes No If Yes, please sign and submit, no further information is required
Provider Signature

4-Alternative Therapy to Schedule II Opioid

Alternative therapy to Schedule II opioid drugs. Complete list of KPMAS VA Medicaid formulary can be found at:

https://healthy.kaiserpermanente.org/static/health/pdfs/formulary/mid/mid\_medicaid.pdf

Preferred Alternative Products: NSAIDs topical and oral; SNRI; Tricyclic Antidepressants; Gabapentin CAPS; Baclofen



### 7-Prescription Monitoring Program (PMP)

7. The prescriber has checked the PMP on the date of this request to determine whether the patient is receiving opioid dosages or dangerous combinations (such as opioids and benzodiazepines) that put him or her at high risk for fatal overdose.

PMP website: <https://www.pmp.dhp.virginia.gov/VAPMPWebCenter/login.aspx>  Yes  No

8. Document the **fill date of the patient's last opioid Rx:** \_\_\_\_\_

9. Document the **fill date for the patient's last benzo Rx:** \_\_\_\_\_ N/A

If benzodiazepine filled in past 30 days, does the prescriber attest that he/she has counseled the patient on the FDA black box warning on the dangers of prescribing Opioids and Benzodiazepines including fatal overdose, has documented that the therapy is medically necessary, and has recorded a tapering plan to achieve the lowest possible effective doses of both opioids and benzodiazepines per the Board of Medicine Opioid Prescribing Regulations?  Yes  No

10. Has naloxone been prescribed for patients with risk factors of prior overdose, substance use disorder, opioid doses in excess of 120 MME/day, or concomitant benzodiazepine?  Yes  No  N/A

### 8- Treatment Plan

11. **For Chronic Pain:** Prescriber attests that a treatment plan with goals that addresses benefits and harm has been established with the patient and the following bullets are included and there is a **SIGNED AGREEMENT** with the patient. This will be reviewed with the patient within 1 to 4 weeks of starting opioid therapy for chronic pain, with dose escalation and is reviewed every 3 months or more frequently.  Yes  No

(Sample Physician/Patient Agreement: [www.drugabuse.gov/sites/default/files/files/samplepatientagreementforms.pdf](http://www.drugabuse.gov/sites/default/files/files/samplepatientagreementforms.pdf))

12. **For Chronic Pain:** The prescriber has ordered and reviewed a urine drug screen (UDS) or serum medication level prior to initiating treatment with short or long-acting opioids?  Yes  No

13. **For Chronic Pain PA renewals,** has the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level at least every 3 months for the first year of treatment and at least every 6 months thereafter to ensure adherence?  Yes  No  N/A

14. If patient exhibits any signs of opioids use disorder, please consider referring the patient to a substance use disorder treatment program?  Yes  No

15. If **no** to any of the above, please explain or provide clinical rationale: \_\_\_\_\_

\_\_\_\_\_

### 9- Provider Sign off

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Physician Signature _____	Date: _____
---------------------------	-------------

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this tele copied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility